Header Image

Investor Relations

Investor Relations

Investor Relations

Corporate Profile

Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, email us.

$5.37 - 0.01
Mar 16, 2018 at 4:00 PM ET
Intraday data provided by eSignal


Nov 16, 2017
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to pro...
Read More
Nov 7, 2017
BCX7353 Phase 3 program agreed with FDA and EMA U.S. Orphan Drug designation for BCX7353 received from FDA RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- B...
Read More

Investor Relations

Thomas Staab, Senior Vice President,
Chief Financial Officer

Proxy Online

For more information click here.

Stockholder Services

Questions about stock transfers and lost certificates should be directed to the transfer agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
1-800-937-5449 (toll free in US and Canada)
1-718-921-8200 (callers outside the US and Canada)